Author(s):
|
Vriens, B.E.; Aarts, M.J.; Vries, B. de; Gastel, S.M. van; Wals, J.;
Smilde, T.J.
; Warmerdam, L.J. van;
Boer, M. de
;
Spronsen, D.J. van
;
Borm, G.F.
;
Tjan-Heijnen, V.C.
; Stienen, J.J.C.;
Hermens, R.P.M.G.
;
Wennekes, L.
; Schans, S.A. van de;
Dekker, H.M.
;
Blijlevens, N.M.A.
;
Maazen, R.W.M. van der
;
Adang, E.M.M.
;
Krieken, J.H.J.M. van
;
Ottevanger, P.B.
; et al.
|
Subject:
|
N4i 2: Invasive mycoses and compromised host ONCOL 3: Translational research NCEBP 2:Evaluation of complex medical interventions ONCOL 4:Quality of Care NCEBP 4: Quality of hospital and integrated care NCEBP 4: Quality of hospital and integrated care ONCOL 4: Quality of Care NCEBP 6: Quality of nursing and allied health care NCEBP 7: Effective primary care and public health ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology ONCOL 4: Quality of Care NCEBP 4: Quality of hospital and integrated care ONCOL 5: Aetiology, screening and detection NCEBP 6: Quality of nursing and allied health care ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology Tijdelijke code tbv inlezen publicaties Radboudumc - Alleen voor gebruik door Radboudumc |
Organization:
|
Internal Medicine Medical Oncology IQ Healthcare Radiology Haematology Radiation Oncology Primary and Community Care Health Evidence Pathology |
Journal title:
|
European Journal of Cancer
|
Abstract:
|
Abstract
BACKGROUND: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients.
PATIENTS AND METHODS: Women with newly diagnosed breast cancer were randomly assigned to neoadjuvant chemotherapy of four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC 60/600 - T 100mg/m(2)) or six cycles of TAC (75/50/500mg/m(2)) every 3 weeks. The primary endpoint was the pathologic complete response (pCR) rate, defined as no invasive tumour present in the breast.
RESULTS: In total, 201 patients were included. Baseline characteristics were well balanced. AC-T resulted in pCR in 21% and TAC in 16% of patients (odds ratio 1.44 (95% confidence interval (CI) 0.67-3.10). AC-T without primary granulocyte-colony stimulating factor (G-CSF) prophylaxis was associated with more febrile neutropenia compared to TAC with primary G-CSF prophylaxis (23% versus 9%), and with more grade 3/4 sensory neuropathy (5% versus 0%).
CONCLUSIONS: With a higher cumulative dose for the concurrent arm, no differences were observed between the two treatment arms with respect to pCR rate. The differential toxicity profile could partly be explained by different use of primary G-CSF prophylaxis.
Copyright © 2013 Elsevier Ltd. All rights reserved.
KEYWORDS: Breast cancer, Cyclophosphamide, Docetaxel, Doxorubicin, Neoadjuvant chemotherapy
|